Share This Page
Drug Price Trends for LICART
✉ Email this page to a colleague
Average Pharmacy Cost for LICART
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LICART 1.3% PATCH | 71858-0305-05 | 24.71134 | EACH | 2024-07-01 |
| LICART 1.3% PATCH | 71858-0305-04 | 24.71134 | EACH | 2024-07-01 |
| LICART 1.3% PATCH | 71858-0305-04 | 24.06941 | EACH | 2024-06-19 |
| LICART 1.3% PATCH | 71858-0305-05 | 24.06941 | EACH | 2024-06-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Licart
Introduction to Licart
Licart, also known as diclofenac epolamine, is a topical nonsteroidal anti-inflammatory drug (NSAID) approved by the FDA for the treatment of acute pain due to minor strains, sprains, and contusions. It is the first and only once-a-day topical NSAID therapy available in the market[1].
Market Overview of Topical NSAIDs
The market for topical NSAIDs, including Licart, is part of the broader diclofenac market. This market is driven by several key factors, including the increasing incidence of sports injuries, the growing geriatric population, and the need for effective pain management solutions.
Diclofenac Market Size and Growth
The diclofenac market is projected to reach $6.1 billion by 2027, growing at a CAGR of 3.9% from 2022 to 2027. North America holds a dominant market share due to robust medical infrastructure and high disease literacy[4].
Segmentation and Growth Drivers
- Geographical Segmentation: North America, particularly the United States, dominates the market due to advanced healthcare infrastructure and high healthcare expenditure. However, the Asia-Pacific region is expected to offer significant growth opportunities due to increasing medical awareness and government support for medicinal developments[4].
- Indication Segmentation: Licart falls under the category of treating acute pain from minor strains, sprains, and contusions. Other indications for diclofenac include osteoarthritis, ankylosing spondylitis, dysmenorrhea, and rheumatoid arthritis[4].
Price Dynamics in the Pharmaceutical Market
The pharmaceutical market, including brand-name drugs like Licart, is experiencing complex price dynamics. Here are some key points:
- List Price vs. Net Price: While list prices for brand-name drugs continue to grow at mid-single-digit rates, net prices have been declining for six consecutive years. In 2023, net prices dropped by 3.0%, and after adjusting for inflation, they plummeted by 7.4%[2].
- Gross-to-Net Bubble: The gap between list and net prices, known as the gross-to-net bubble, continues to inflate. This gap is due to rebates and discounts that reduce the selling prices of brand-name drugs[2].
Price Projections for Licart
Given the broader trends in the pharmaceutical market:
- Initial Pricing: Licart, being a new entrant in the market, is likely to be priced competitively with other topical NSAIDs. Its once-a-day application and patented next-generation patch technology could justify a premium pricing strategy[1].
- Future Adjustments: As with other brand-name drugs, Licart's net price may see adjustments over time due to rebates, discounts, and regulatory pressures. The Inflation Reduction Act of 2022, for example, may discourage manufacturers from increasing list prices beyond the rate of inflation[2].
Market Competition and Adoption
Licart competes in a market where other topical NSAIDs and pain relief products are available. However, its unique once-a-day application and fast onset of pain relief could drive adoption.
- Clinical Efficacy: The efficacy and safety of Licart, similar to other diclofenac products, will be crucial in driving market acceptance and growth[1].
- Regulatory Environment: The regulatory landscape, including provisions like those in the Inflation Reduction Act, will influence pricing strategies and market access for Licart[2].
Regional Market Outlook
- United States: This region is expected to be a significant market for Licart due to the high incidence of sports injuries and the presence of robust medical infrastructure[4].
- Other Regions: While North America dominates, other regions such as the Asia-Pacific are expected to grow rapidly due to increasing healthcare spending and government support[4].
Key Takeaways
- Market Growth: The diclofenac market, including Licart, is expected to grow at a CAGR of 3.9% from 2022 to 2027.
- Price Dynamics: Net prices for brand-name drugs, including Licart, are likely to decline due to rebates and discounts.
- Regulatory Impact: The Inflation Reduction Act of 2022 will influence pricing strategies and market access.
- Regional Focus: The United States and Asia-Pacific regions will be key markets for Licart.
FAQs
Q: What is Licart used for? A: Licart is used to treat acute pain due to minor strains, sprains, and contusions.
Q: How often is Licart applied? A: Licart is applied once a day, making it a convenient option for pain management.
Q: What is the market outlook for Licart? A: The market for Licart is part of the broader diclofenac market, which is expected to grow at a CAGR of 3.9% from 2022 to 2027.
Q: How do regulatory changes affect Licart's pricing? A: Regulatory changes, such as the Inflation Reduction Act of 2022, may discourage manufacturers from increasing list prices beyond the rate of inflation.
Q: Which regions are expected to drive the growth of Licart? A: The United States and the Asia-Pacific region are expected to be significant markets for Licart.
Cited Sources
- IBSA Pharma Inc. - "Licart™ Now Available to Treat Acute Pain Due to Minor Strains, Sprains, and Contusions"[1]
- Drug Channels - "Tales of the Unsurprised: U.S. Brand-Name Drug Prices Fell for an Unprecedented Sixth Consecutive Year"[2]
- Future Market Insights - "PCSK9 Inhibitors Market Growth & Revenue Forecast 2024-2034"[3]
- IndustryARC - "Diclofenac Market Size Report, 2022-2027"[4]
More… ↓
